Enteromedics Inc (ETRM) 0.37 $ETRM
EnteroMedics Announces First-of-its-Kind Procedure with vBloc® Therapy Used as Adjunctive Rescue Treatment for Failed Gastric Sleeve in Patients with Obesity
PR Newswire - Wed Jun 01, 6:00AM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced a first-of-its-kind procedure in which the Company's vBloc® Neurometabolic Therapy was used as an adjunctive rescue treatment in two patients with obesity who failed to achieve sufficient weight loss and diabetes control with their previous gastric sleeve surgeries.
ETRM: 0.37 (-0.05)
EnteroMedics to Host vBloc® Commercialization Update Conference Call
PR Newswire - Mon May 23, 6:00AM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that, as previously guided, it will host a conference call to provide an update on the commercialization of the Company's vBloc® Neurometabolic Therapy on Wednesday, June 1, 2016 at 11:00 AM Eastern Time. The call will be led by Dan W. Gladney, the Company's President and Chief Executive Officer.
ETRM: 0.37 (-0.05)
EnteroMedics Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 05, 3:19PM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three months ended March 31, 2016.
ETRM: 0.37 (-0.05)
EnteroMedics Announces Closing of $6.25 Million Third Tranche of Previously-Announced Convertible Notes Offering
PR Newswire - Tue May 03, 6:00AM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the third tranche of the $25 million Senior Amortizing Convertible Notes (the "Notes"
offering announced on November 5, 2015, has closed, for proceeds of $6.25 million. Prior to this most recent closing, EnteroMedics received $12.5 million in proceeds under the agreement. The original securities purchase agreement, which consisted of three tranches, has been amended to allow for a fourth tranche of $6.25 Million. This final tranche must be drawn or waived on or prior to August 15, 2016. The Company intends to use the net proceeds from this offering to continue its commercialization efforts for the Maestro Rechargeable System, for clinical and product development activities and for other working capital and general corporate purposes.
ETRM: 0.37 (-0.05)
EnteroMedics Announces Exclusive Federal Government Business Channel Sales Agreement with Academy Medical to Provide vBloc® Neurometabolic Therapy to US Department of Veterans Affairs Medical Facilities
PR Newswire - Mon May 02, 6:00AM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced an exclusive federal government business channel sales agreement with Academy Medical, LLC to sell its vBloc® Neurometabolic Therapy to U.S. Department of Veterans Affairs (VA) medical facilities. Academy Medical is a certified Service-Disabled Veteran-Owned Small Business specializing in the distribution of medical products to VA and Department of Defense (DoD) hospitals and community-based outpatient clinics.
ETRM: 0.37 (-0.05)
Weight Loss Surgery Foundation of America to Include EnteroMedics vBloc® Therapy as Part of the Grant Referral Program
PR Newswire - Thu Apr 21, 6:00AM CDT
Weight Loss Surgery Foundation of America and EnteroMedics Inc. (NASDAQ: ETRM) announced today that Weight Loss Surgery Foundation of America will include EnteroMedics vBloc® Therapy in their grant referral program starting June 1, 2016.
ETRM: 0.37 (-0.05)
EnteroMedics Announces Publication of Results Showing Significantly Greater Weight Loss in vBloc® Patients with Moderate Obesity
PR Newswire - Tue Apr 05, 1:44PM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the publication of results from the Company's ReCharge Study on the effect of vBloc® Neurometabolic Therapy in patients with moderate obesity with an obesity-related comorbid condition. In this population, patients saw 74% greater weight loss with vBloc therapy compared to a rigorous sham control, resulting in an average loss of 33% of excess weight at 12 months. Further, three quarters of patients lost at least 20% of their excess weight and a quarter lost at least 50%. The publication, entitled "Effect of Vagal Nerve Blockade on Moderate Obesity with an Obesity-Related Comorbid Condition: The ReCharge Study," was published in the journal Obesity Surgery and is available online here.
ETRM: 0.37 (-0.05)
EnteroMedics to Present at the 28th Annual ROTH Conference
PR Newswire - Wed Mar 09, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Dan Gladney, Chief Executive Officer, will present at the 28th Annual ROTH Conference on Tuesday, March 15, 2016 at 11:00 AM Pacific Time at the Ritz Carlton in Dana Point, CA.
ETRM: 0.37 (-0.05)
EnteroMedics to Host Fourth Quarter 2015 Financial Results and Commercialization Update Conference Call
PR Newswire - Wed Feb 03, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it will host a conference call on Wednesday, February 17, 2016 at 11:00 AM Eastern Time to discuss financial results for the fourth quarter ended December 31, 2015 and to provide an update on the commercialization of the Company's vBloc® Neurometabolic Therapy.
ETRM: 0.37 (-0.05)
Winthrop-University Hospital Becomes First Employer in the U.S. to Cover Innovative Obesity Treatment vBloc Therapy
PR Newswire - Tue Feb 02, 4:44PM CST
Winthrop-University Hospital and EnteroMedics Inc. announced today that Winthrop-University Hospital has become the first employer in the United States to add vBloc Neurometabolic Therapy as an included benefit for its nearly 8,000 eligible employees and their spouses. As a leader in the field of bariatric surgery, Winthrop-University Hospital recently made headlines as an innovator with vBloc Therapy, as one of the first sites in the country to offer this treatment for obesity to its patients. Winthrop-University Hospital is a vBloc Institute and part of EnteroMedics' IDN Partnership program.
ETRM: 0.37 (-0.05)
EnteroMedics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Fri Jan 22, 4:22PM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that, in accordance with NASDAQ Listing Rule 5635(c)(4), its Board of Directors has approved inducement awards as a component of employment compensation for three recently appointed executives: Paul Hickey, Senior Vice President of Marketing and Reimbursement, Nick Ansari, Senior Vice President of Sales, and Peter DeLange, Senior Vice President of Operations and Business Development.
ETRM: 0.37 (-0.05)
EnteroMedics Announces Closing of $11 Million Tranche from Previously-Announced Convertible Notes Offering
PR Newswire - Wed Jan 13, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the second tranche of the $25 million Senior Amortizing Convertible Notes (the "Notes" offering announced on November 5, 2015, has closed, for proceeds of $11 million. EnteroMedics received $1.5 million at the initial closing on November 9, 2015. The third and final tranche, for proceeds of $12.5 million, is scheduled to fund in approximately 45 days. The Company intends to use the net proceeds from this offering to continue its commercialization efforts for the Maestro Rechargeable System, for clinical and product development activities and for other working capital and general corporate purposes.
ETRM: 0.37 (-0.05)
EnteroMedics Announces Senior Level Appointments, New Commercial Operations Organization Structure
PR Newswire - Wed Jan 06, 3:53PM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced senior level appointments within its newly reorganized commercial operations group. The appointments include Paul Hickey as Senior Vice President of Marketing and Reimbursement, Nick Ansari as Senior Vice President of Sales, and Peter Delange as Senior Vice President of Operations and Business Development. With the addition of these new roles, EnteroMedics is shifting its commercial organization toward several, highly focused commercial areas headed by executives with significant leadership experience.
ETRM: 0.37 (-0.05)
EnteroMedics Announces Publication in SOARD of ASMBS Position Statement on Vagal Blocking Therapy for Obesity
PR Newswire - Tue Jan 05, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the publication of a position statement on vagal blocking therapy for obesity by Pavlos Papasavas, MD, Maher El Chaar, MD and Shanu N. Kothari, MD, on behalf of the American Society for Metabolic and Bariatric Surgery (ASMBS), in the journal Surgery for Obesity and Related Diseases. The position statement was prepared after review by the ASMBS Clinical Issues Committee and is available online here.
ETRM: 0.37 (-0.05)
STERIS (STE) Hits 52-Week High on Robust FY16 Outlook
Zacks Equity Research - Zacks Investment Research - Thu Dec 31, 12:35PM CST
STERIS' shares closed at $76.95 yesterday, translating into a decent one-year return of around 18.1%.
ETRM: 0.37 (-0.05), MASI: 50.89 (-1.49), STE: 65.36 (-4.03), EXAC: 25.57 (-0.73)
STERIS Up on Robust FY16 Outlook; Segments Reorganized
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 1:30PM CST
The Synergy health acquisition has enabled STERIS (STE) to expand its already robust presence in North America to the developed markets of Europe as well as the emerging markets of Asia-Pacific and Latin America.
ABMD: 100.81 (-3.44), ETRM: 0.37 (-0.05), MASI: 50.89 (-1.49), STE: 65.36 (-4.03)
EnteroMedics Announces 1-for-15 Reverse Split
PR Newswire - Wed Dec 23, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced shareholder approval for three proposals: (1) an amendment to the Company's Fifth Amended and Restated Certificate of Incorporation to effect a reverse split of its issued and outstanding shares of common stock; (2) an increase in the number of shares of common stock authorized for issuance effective after the reverse stock split; and (3) the issuance of shares of the Company's common stock underlying convertible notes and warrants issued by EnteroMedics pursuant to the terms of a securities purchase agreement dated November 4, 2015.
ETRM: 0.37 (-0.05)
EnteroMedics to Host Year-end Company Update Conference Call
PR Newswire - Tue Dec 08, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that, as previously guided, it will host a year-end conference call on Thursday, December 17, 2015 at 11:00 AM Eastern Time to provide an update on the commercialization of the Company's vBloc® Neurometabolic Therapy, delivered via the Maestro® System, as well as other recent Company developments. The call will be led by Dan W. Gladney, the Company's recently appointed President and Chief Executive Officer.
ETRM: 0.37 (-0.05)
EnteroMedics Announces First-of-its-Kind Procedure with vBloc® Therapy Used as Adjunctive Rescue Treatment for Failed Gastric Sleeve in Patients with Obesity
PR Newswire - Wed Jun 01, 6:00AM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced a first-of-its-kind procedure in which the Company's vBloc® Neurometabolic Therapy was used as an adjunctive rescue treatment in two patients with obesity who failed to achieve sufficient weight loss and diabetes control with their previous gastric sleeve surgeries.
ETRM: 0.37 (-0.05)
EnteroMedics to Host vBloc® Commercialization Update Conference Call
PR Newswire - Mon May 23, 6:00AM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that, as previously guided, it will host a conference call to provide an update on the commercialization of the Company's vBloc® Neurometabolic Therapy on Wednesday, June 1, 2016 at 11:00 AM Eastern Time. The call will be led by Dan W. Gladney, the Company's President and Chief Executive Officer.
ETRM: 0.37 (-0.05)
EnteroMedics Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 05, 3:19PM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three months ended March 31, 2016.
ETRM: 0.37 (-0.05)
EnteroMedics Announces Closing of $6.25 Million Third Tranche of Previously-Announced Convertible Notes Offering
PR Newswire - Tue May 03, 6:00AM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the third tranche of the $25 million Senior Amortizing Convertible Notes (the "Notes"
offering announced on November 5, 2015, has closed, for proceeds of $6.25 million. Prior to this most recent closing, EnteroMedics received $12.5 million in proceeds under the agreement. The original securities purchase agreement, which consisted of three tranches, has been amended to allow for a fourth tranche of $6.25 Million. This final tranche must be drawn or waived on or prior to August 15, 2016. The Company intends to use the net proceeds from this offering to continue its commercialization efforts for the Maestro Rechargeable System, for clinical and product development activities and for other working capital and general corporate purposes. ETRM: 0.37 (-0.05)
EnteroMedics Announces Exclusive Federal Government Business Channel Sales Agreement with Academy Medical to Provide vBloc® Neurometabolic Therapy to US Department of Veterans Affairs Medical Facilities
PR Newswire - Mon May 02, 6:00AM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced an exclusive federal government business channel sales agreement with Academy Medical, LLC to sell its vBloc® Neurometabolic Therapy to U.S. Department of Veterans Affairs (VA) medical facilities. Academy Medical is a certified Service-Disabled Veteran-Owned Small Business specializing in the distribution of medical products to VA and Department of Defense (DoD) hospitals and community-based outpatient clinics.
ETRM: 0.37 (-0.05)
Weight Loss Surgery Foundation of America to Include EnteroMedics vBloc® Therapy as Part of the Grant Referral Program
PR Newswire - Thu Apr 21, 6:00AM CDT
Weight Loss Surgery Foundation of America and EnteroMedics Inc. (NASDAQ: ETRM) announced today that Weight Loss Surgery Foundation of America will include EnteroMedics vBloc® Therapy in their grant referral program starting June 1, 2016.
ETRM: 0.37 (-0.05)
EnteroMedics Announces Publication of Results Showing Significantly Greater Weight Loss in vBloc® Patients with Moderate Obesity
PR Newswire - Tue Apr 05, 1:44PM CDT
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the publication of results from the Company's ReCharge Study on the effect of vBloc® Neurometabolic Therapy in patients with moderate obesity with an obesity-related comorbid condition. In this population, patients saw 74% greater weight loss with vBloc therapy compared to a rigorous sham control, resulting in an average loss of 33% of excess weight at 12 months. Further, three quarters of patients lost at least 20% of their excess weight and a quarter lost at least 50%. The publication, entitled "Effect of Vagal Nerve Blockade on Moderate Obesity with an Obesity-Related Comorbid Condition: The ReCharge Study," was published in the journal Obesity Surgery and is available online here.
ETRM: 0.37 (-0.05)
EnteroMedics to Present at the 28th Annual ROTH Conference
PR Newswire - Wed Mar 09, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Dan Gladney, Chief Executive Officer, will present at the 28th Annual ROTH Conference on Tuesday, March 15, 2016 at 11:00 AM Pacific Time at the Ritz Carlton in Dana Point, CA.
ETRM: 0.37 (-0.05)
EnteroMedics to Host Fourth Quarter 2015 Financial Results and Commercialization Update Conference Call
PR Newswire - Wed Feb 03, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it will host a conference call on Wednesday, February 17, 2016 at 11:00 AM Eastern Time to discuss financial results for the fourth quarter ended December 31, 2015 and to provide an update on the commercialization of the Company's vBloc® Neurometabolic Therapy.
ETRM: 0.37 (-0.05)
Winthrop-University Hospital Becomes First Employer in the U.S. to Cover Innovative Obesity Treatment vBloc Therapy
PR Newswire - Tue Feb 02, 4:44PM CST
Winthrop-University Hospital and EnteroMedics Inc. announced today that Winthrop-University Hospital has become the first employer in the United States to add vBloc Neurometabolic Therapy as an included benefit for its nearly 8,000 eligible employees and their spouses. As a leader in the field of bariatric surgery, Winthrop-University Hospital recently made headlines as an innovator with vBloc Therapy, as one of the first sites in the country to offer this treatment for obesity to its patients. Winthrop-University Hospital is a vBloc Institute and part of EnteroMedics' IDN Partnership program.
ETRM: 0.37 (-0.05)
EnteroMedics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Fri Jan 22, 4:22PM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that, in accordance with NASDAQ Listing Rule 5635(c)(4), its Board of Directors has approved inducement awards as a component of employment compensation for three recently appointed executives: Paul Hickey, Senior Vice President of Marketing and Reimbursement, Nick Ansari, Senior Vice President of Sales, and Peter DeLange, Senior Vice President of Operations and Business Development.
ETRM: 0.37 (-0.05)
EnteroMedics Announces Closing of $11 Million Tranche from Previously-Announced Convertible Notes Offering
PR Newswire - Wed Jan 13, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the second tranche of the $25 million Senior Amortizing Convertible Notes (the "Notes"
offering announced on November 5, 2015, has closed, for proceeds of $11 million. EnteroMedics received $1.5 million at the initial closing on November 9, 2015. The third and final tranche, for proceeds of $12.5 million, is scheduled to fund in approximately 45 days. The Company intends to use the net proceeds from this offering to continue its commercialization efforts for the Maestro Rechargeable System, for clinical and product development activities and for other working capital and general corporate purposes. ETRM: 0.37 (-0.05)
EnteroMedics Announces Senior Level Appointments, New Commercial Operations Organization Structure
PR Newswire - Wed Jan 06, 3:53PM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced senior level appointments within its newly reorganized commercial operations group. The appointments include Paul Hickey as Senior Vice President of Marketing and Reimbursement, Nick Ansari as Senior Vice President of Sales, and Peter Delange as Senior Vice President of Operations and Business Development. With the addition of these new roles, EnteroMedics is shifting its commercial organization toward several, highly focused commercial areas headed by executives with significant leadership experience.
ETRM: 0.37 (-0.05)
EnteroMedics Announces Publication in SOARD of ASMBS Position Statement on Vagal Blocking Therapy for Obesity
PR Newswire - Tue Jan 05, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the publication of a position statement on vagal blocking therapy for obesity by Pavlos Papasavas, MD, Maher El Chaar, MD and Shanu N. Kothari, MD, on behalf of the American Society for Metabolic and Bariatric Surgery (ASMBS), in the journal Surgery for Obesity and Related Diseases. The position statement was prepared after review by the ASMBS Clinical Issues Committee and is available online here.
ETRM: 0.37 (-0.05)
STERIS (STE) Hits 52-Week High on Robust FY16 Outlook
Zacks Equity Research - Zacks Investment Research - Thu Dec 31, 12:35PM CST
STERIS' shares closed at $76.95 yesterday, translating into a decent one-year return of around 18.1%.
ETRM: 0.37 (-0.05), MASI: 50.89 (-1.49), STE: 65.36 (-4.03), EXAC: 25.57 (-0.73)
STERIS Up on Robust FY16 Outlook; Segments Reorganized
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 1:30PM CST
The Synergy health acquisition has enabled STERIS (STE) to expand its already robust presence in North America to the developed markets of Europe as well as the emerging markets of Asia-Pacific and Latin America.
ABMD: 100.81 (-3.44), ETRM: 0.37 (-0.05), MASI: 50.89 (-1.49), STE: 65.36 (-4.03)
EnteroMedics Announces 1-for-15 Reverse Split
PR Newswire - Wed Dec 23, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced shareholder approval for three proposals: (1) an amendment to the Company's Fifth Amended and Restated Certificate of Incorporation to effect a reverse split of its issued and outstanding shares of common stock; (2) an increase in the number of shares of common stock authorized for issuance effective after the reverse stock split; and (3) the issuance of shares of the Company's common stock underlying convertible notes and warrants issued by EnteroMedics pursuant to the terms of a securities purchase agreement dated November 4, 2015.
ETRM: 0.37 (-0.05)
EnteroMedics to Host Year-end Company Update Conference Call
PR Newswire - Tue Dec 08, 6:00AM CST
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that, as previously guided, it will host a year-end conference call on Thursday, December 17, 2015 at 11:00 AM Eastern Time to provide an update on the commercialization of the Company's vBloc® Neurometabolic Therapy, delivered via the Maestro® System, as well as other recent Company developments. The call will be led by Dan W. Gladney, the Company's recently appointed President and Chief Executive Officer.
ETRM: 0.37 (-0.05)
